SEC Form SC 13D/A filed by Lument Finance Trust Inc. (Amendment)

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A

(Rule 13d-101)

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

This Amendment No. 1 (“Amendment No. 1”) amends and supplements the statement on Schedule 13D, dated February 22, 2022 (the “Schedule 13D”), filed with the Securities and Exchange Commission relating to the common stock, par value $0.01 per share (“Common Stock”), of Lument Finance Trust, Inc., a Maryland corporation (the “Company”), and is being filed pursuant to Rule 13d-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”).  The address of the principal executive office of the Company is 230 Park Avenue, 19th Floor, New York, New York 10169.

This Amendment No. 1 is being filed to supplement the information provided under Item 6 as a result of the execution of a director designation agreement as described in Item 6.

The information in Item 6 is hereby amended and supplemented by adding the following:

On April 26, 2022, the Company entered into a Director Designation Agreement with OREC Investment Holdings, LLC (“OREC IH”) (the “Director Designation Agreement”) pursuant to which the Company granted OREC IH the right to designate a nominee to the Company’s board of directors. Pursuant to the Director Designation Agreement, Marie D. Reynolds has been designated by OREC IH and nominated by the Company for election to the board of directors at its 2022 Annual Meeting of Stockholders. The right granted expires at such time as the beneficial ownership of OREC IH of the Company’s common stock, determined pursuant to Rule 13d-3 under the Exchange Act of 1934, as amended, is less than 5%. Prior to such time, the Company has agreed to include the OREC IH designee and the chief executive officer of OREC Investment Management, LLC, in its slate of nominees for election at each annual meeting of stockholders.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: April 29, 2022